Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival rate at 6 months
progression-free survival wad defined as the time from the date of enrollment to the date of the first occurrence of objective disease progression or death from any cause, which occur first.
6 months
No
MJ Kang, MD, MSc
Study Director
Asan Medical Center
Korea: Institutional Review Board
AMC_0803
NCT01375972
March 2008
August 2011
Name | Location |
---|